Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries

Richard D. Rheingans, Dagna Constenla, Lynn Antil, Bruce L. Innis, Thomas Breuer

Research output: Contribution to journalArticle

Abstract

Objectives. To estimate the costs, benefits and cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries: Argentina, Brazil, Chile, the Dominican Republic, Honduras, Mexico, Panama, and Venezuela. Methods. An economic model was constructed to estimate the cost-effectiveness of vaccination from the health care system perspective, using national administrative and published epidemiological evidence, country-specific cost estimates, and vaccine efficacy data. The model was applied to the first five years of life for the 2003 birth cohort in each country. The main health outcome was the disability-adjusted life year (DALY), and the main summary measure was the incremental cost per DALY averted. A 3% discount rate was used for all predicted costs and benefits. Sensitivity analyses evaluated the impact of uncertainty regarding key variables on cost-effectiveness estimates. Results. According to the estimates obtained with the economic model, vaccination would prevent more than 65% of the medical visits, deaths, and treatment costs associated with rotavirus gastroenteritis in the eight countries analyzed here. At a cost of US$ 24 per course (for a two-dose vaccine), the incremental cost-effectiveness ratio ranged from US$ 269/DALY in Honduras to US$ 10 656/DALY in Chile. Cost-effectiveness ratios were sensitive to assumptions about vaccine price, mortality, and vaccine efficacy. Conclusions. Vaccination would effectively reduce the disease burden and health care costs of rotavirus gastroenteritis in the Latin American and Caribbean countries analyzed here. From the health care system perspective, universal vaccination of infants is predicted to be cost-effective, based on current standards.

Original languageEnglish (US)
Pages (from-to)205-216
Number of pages12
JournalRevista Panamericana de Salud Publica/Pan American Journal of Public Health
Volume21
Issue number4
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

gastroenteritis
vaccination
Rotavirus
Gastroenteritis
Cost-Benefit Analysis
Vaccination
Quality-Adjusted Life Years
costs
cost
Vaccines
disability
Honduras
vaccine
Economic Models
Costs and Cost Analysis
Chile
Health Care Costs
health care
Dominican Republic
Panama

Keywords

  • Caribbean region
  • Cost-benefit analysis
  • Latin America
  • Models, economic
  • Rotavirus
  • Rotavirus vaccines

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Geography, Planning and Development

Cite this

Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. / Rheingans, Richard D.; Constenla, Dagna; Antil, Lynn; Innis, Bruce L.; Breuer, Thomas.

In: Revista Panamericana de Salud Publica/Pan American Journal of Public Health, Vol. 21, No. 4, 04.2007, p. 205-216.

Research output: Contribution to journalArticle

@article{14df6c3161b94795aac317059b23fc30,
title = "Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries",
abstract = "Objectives. To estimate the costs, benefits and cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries: Argentina, Brazil, Chile, the Dominican Republic, Honduras, Mexico, Panama, and Venezuela. Methods. An economic model was constructed to estimate the cost-effectiveness of vaccination from the health care system perspective, using national administrative and published epidemiological evidence, country-specific cost estimates, and vaccine efficacy data. The model was applied to the first five years of life for the 2003 birth cohort in each country. The main health outcome was the disability-adjusted life year (DALY), and the main summary measure was the incremental cost per DALY averted. A 3{\%} discount rate was used for all predicted costs and benefits. Sensitivity analyses evaluated the impact of uncertainty regarding key variables on cost-effectiveness estimates. Results. According to the estimates obtained with the economic model, vaccination would prevent more than 65{\%} of the medical visits, deaths, and treatment costs associated with rotavirus gastroenteritis in the eight countries analyzed here. At a cost of US$ 24 per course (for a two-dose vaccine), the incremental cost-effectiveness ratio ranged from US$ 269/DALY in Honduras to US$ 10 656/DALY in Chile. Cost-effectiveness ratios were sensitive to assumptions about vaccine price, mortality, and vaccine efficacy. Conclusions. Vaccination would effectively reduce the disease burden and health care costs of rotavirus gastroenteritis in the Latin American and Caribbean countries analyzed here. From the health care system perspective, universal vaccination of infants is predicted to be cost-effective, based on current standards.",
keywords = "Caribbean region, Cost-benefit analysis, Latin America, Models, economic, Rotavirus, Rotavirus vaccines",
author = "Rheingans, {Richard D.} and Dagna Constenla and Lynn Antil and Innis, {Bruce L.} and Thomas Breuer",
year = "2007",
month = "4",
language = "English (US)",
volume = "21",
pages = "205--216",
journal = "Revista Panamericana de Salud Publica/Pan American Journal of Public Health",
issn = "1020-4989",
publisher = "Pan American Health Organization",
number = "4",

}

TY - JOUR

T1 - Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries

AU - Rheingans, Richard D.

AU - Constenla, Dagna

AU - Antil, Lynn

AU - Innis, Bruce L.

AU - Breuer, Thomas

PY - 2007/4

Y1 - 2007/4

N2 - Objectives. To estimate the costs, benefits and cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries: Argentina, Brazil, Chile, the Dominican Republic, Honduras, Mexico, Panama, and Venezuela. Methods. An economic model was constructed to estimate the cost-effectiveness of vaccination from the health care system perspective, using national administrative and published epidemiological evidence, country-specific cost estimates, and vaccine efficacy data. The model was applied to the first five years of life for the 2003 birth cohort in each country. The main health outcome was the disability-adjusted life year (DALY), and the main summary measure was the incremental cost per DALY averted. A 3% discount rate was used for all predicted costs and benefits. Sensitivity analyses evaluated the impact of uncertainty regarding key variables on cost-effectiveness estimates. Results. According to the estimates obtained with the economic model, vaccination would prevent more than 65% of the medical visits, deaths, and treatment costs associated with rotavirus gastroenteritis in the eight countries analyzed here. At a cost of US$ 24 per course (for a two-dose vaccine), the incremental cost-effectiveness ratio ranged from US$ 269/DALY in Honduras to US$ 10 656/DALY in Chile. Cost-effectiveness ratios were sensitive to assumptions about vaccine price, mortality, and vaccine efficacy. Conclusions. Vaccination would effectively reduce the disease burden and health care costs of rotavirus gastroenteritis in the Latin American and Caribbean countries analyzed here. From the health care system perspective, universal vaccination of infants is predicted to be cost-effective, based on current standards.

AB - Objectives. To estimate the costs, benefits and cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries: Argentina, Brazil, Chile, the Dominican Republic, Honduras, Mexico, Panama, and Venezuela. Methods. An economic model was constructed to estimate the cost-effectiveness of vaccination from the health care system perspective, using national administrative and published epidemiological evidence, country-specific cost estimates, and vaccine efficacy data. The model was applied to the first five years of life for the 2003 birth cohort in each country. The main health outcome was the disability-adjusted life year (DALY), and the main summary measure was the incremental cost per DALY averted. A 3% discount rate was used for all predicted costs and benefits. Sensitivity analyses evaluated the impact of uncertainty regarding key variables on cost-effectiveness estimates. Results. According to the estimates obtained with the economic model, vaccination would prevent more than 65% of the medical visits, deaths, and treatment costs associated with rotavirus gastroenteritis in the eight countries analyzed here. At a cost of US$ 24 per course (for a two-dose vaccine), the incremental cost-effectiveness ratio ranged from US$ 269/DALY in Honduras to US$ 10 656/DALY in Chile. Cost-effectiveness ratios were sensitive to assumptions about vaccine price, mortality, and vaccine efficacy. Conclusions. Vaccination would effectively reduce the disease burden and health care costs of rotavirus gastroenteritis in the Latin American and Caribbean countries analyzed here. From the health care system perspective, universal vaccination of infants is predicted to be cost-effective, based on current standards.

KW - Caribbean region

KW - Cost-benefit analysis

KW - Latin America

KW - Models, economic

KW - Rotavirus

KW - Rotavirus vaccines

UR - http://www.scopus.com/inward/record.url?scp=34547271207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547271207&partnerID=8YFLogxK

M3 - Article

C2 - 17612464

AN - SCOPUS:34547271207

VL - 21

SP - 205

EP - 216

JO - Revista Panamericana de Salud Publica/Pan American Journal of Public Health

JF - Revista Panamericana de Salud Publica/Pan American Journal of Public Health

SN - 1020-4989

IS - 4

ER -